The role of proteomics in dementia and Alzheimer's disease

Acta Neuropathologica

Volumn 118, Issue 1, 2009, Pages 181-195

  Zellner, Maria ^a   Veitinger, Michael ^a   Umlauf, Ellen ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA ENOLASE; ALPHA1 GLYCOPROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BETA TUBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; CYSTATIN C; FATTY ACID BINDING PROTEIN; FIBRINOGEN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN HEAVY CHAIN; PENTRAXIN; PEROXIREDOXIN 2; PHOSPHOGLYCERATE MUTASE; PROSTAGLANDIN D SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RETINOL BINDING PROTEIN; THIOREDOXIN; TRIOSEPHOSPHATE ISOMERASE; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; FLUORESCENCE; HUMAN; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; NEUROPATHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE STUDY; REVIEW; SEPARATION TECHNIQUE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DEMENTIA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; OXIDATIVE STRESS; PROTEOMICS;

EID: 67349280701     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-009-0502-7     Document Type: Review

References (112)

1. Abdi F, Quinn JF, Jankovic J et al (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293-348
2. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine-oxidase in dementia of Alzheimer type. Life Sci 27:1029-1034. doi: 10.1016/ 0024-3205(80)90025-9
3. Ai KZ, Vermuyten K, Dedeyn PP, Lowenthal A, Karcher D (1989) A serum-protein involved in aging. Mol Chem Neuropathol 11:131-141
4. Aksenov MY, Markesbery WR (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci Lett 302:141-145. doi: 10.1016/ S0304-3940(01)01636-6
5. Alafuzoff I, Adolfsson R, Bucht G, Jellum E, Mehta PD, Winblad B (1986) Isoelectric-focusing and two-dimensional gel-electrophoresis in plasma and cerebrospinal-fluid from patients with dementia. Eur Neurol 25:285-289. doi: 10.1159/000116023
6. Alban A, David SO, Bjorkesten L et al (2003) A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3:36-44. doi: 10.1002/pmic.200390006
7. Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathological changes in nondemented elderly individuals matches the pattern in Alzheimers disease. Neurology 42:1681-1688
8. Blennow K (2005) CSF biomarkers for Alzheimer's disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5:661-672. doi: 10.1586/14737159.5.5.661
9. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2:605-613. doi: 10.1016/S1474-4422(03)00530-1
10. Brechlin P, Jahn O, Steinacker P et al (2008) Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8:4357-4366. doi: 10.1002/pmic.200800375
11. Butterfield DA, Castegna A (2003) Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: Insights into neurodegeneration. Cell Mol Biol 49:747-751
12. Butterfield DA, Sultana R (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: Insights into the progression of this dementing disorder. J Alzheimers Dis 12:61-72
13. Butterfield DA, Sultana R (2008) Identification of 3-nitrotyosine-modified brain proteins by redox proteomics. Nitric oxide, Part F. Methods Enzymol 440:295-308
14. Butterfield DA, Boyd-Kimball D, Castegna A (2003) Proteomics in Alzheimer's disease: Insights into potential mechanisms of neurodegeneration. J Neurochem 86:1313-1327. doi: 10.1046/ j.1471-4159.2003.01948.x
15. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. Eur J Pharmacol 545:39-50. doi: 10.1016/j.ejphar.2006.06.026
16. Carrette O, Demalte I, Scherl A et al (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3:1486-1494. doi: 10.1002/pmic.200300470
17. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28:155-163. doi: 10.1179/016164106X98035
18. Castegna A, Aksenov M, Aksenova M et al (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part 1. Creatine kinase bb, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33:562-571. doi: 10.1016/ S0891-5849(02)00914-0
19. Castegna A, Aksenov M, Thongboonkerd V et al (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524-1532. doi: 10.1046/ j.1471-4159.2002.01103.x
20. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394-1401. doi: 10.1046/ j.1471-4159.2003.01786.x
21. Chait BT, Kent SBH (1992) Weighing naked proteins: Practical, high-accuracy mass measurement of peptides and proteins. Science 257:1885-1894. doi: 10.1126/science.1411504
22. Cheon MS, Kim SH, Fountoulakis M, Lubec G (2003) Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J Neural Trans Suppl 225-234
23. Choe LH, Dutt MJ, Relkin N, Lee KH (2002) Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23:2247-2251. doi: 10.1002/ 1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M
24. Chromy BA, Gonzales AD, Perkins J et al (2004) Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res 3:1120-1127. doi: 10.1021/pr049921p
25. Colciaghi F, Marcello E, Borroni B et al (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62:498-501
26. Davidsson P, Sjogren M, Andreasen N et al (2002) Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 109:128-133. doi: 10.1016/S0169-328X(02)00549-1
27. Davidsson P, Westman-Brinkmalm A, Nilsson CL et al (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13:611-615. doi: 10.1097/00001756-200204160-00015
28. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimers disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-746. doi: 10.1016/S1474-4422(07)70178-3
29. Edgar PF, Schonberger SJ, Dean B, Faull RLM, Kydd R, Cooper GJS (1999) A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol Psychiatry 4:173-178. doi: 10.1038/sj.mp.4000463
30. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989) Electrospray ionization for mass-spectrometry of large biomolecules. Science 246:64-71. doi: 10.1126/science.2675315
31. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61:120-129. doi: 10.1002/ana.21038
32. Fountoulakis M, Cairns N, Lubec G (1999) Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57:323-335
33. Frey HJ, Mattila KM, Korolainen MA, Pirttila T (2005) Problems associated with biological markers of Alzheimer's disease. Neurochem Res 30:1501-1510. doi: 10.1007/s11064-005-8827-7
34. Gatz M, Reynolds CA, Fratiglioni L et al (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63:168-174. doi: 10.1001/archpsyc.63.2.168
35. Gottfries CG (1990) Neurochemical aspects on aging and diseases with cognitive impairment. J Neurosci Res 27:541-547. doi: 10.1002/ jnr.490270415
36. Greber S, Lubec G, Cairns N, Fountoulakis M (1999) Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20:928-934. doi: 10.1002/(SICI)1522-2683(19990101)20:4/5<928::AID-ELPS928>3.0.CO;2-Z
37. Harman D (1956) Aging: A theory based on free-radical and radiation chemistry. J Gerontol 11:298-300
38. Harman D (2003) The free radical theory of aging. Antioxid Redox Signal 5:557-561. doi: 10.1089/152308603770310202
39. Harrington MG, Merril CR, Asher DM, Gajdusek DC (1986) Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N Engl J Med 315:279-383
40. Hayflick L (1998) How and why we age. Exp Gerontol 33:639-653. doi: 10.1016/S0531-5565(98)00023-0
41. Hensley K, Hall N, Subramaniam R et al (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146-2156
42. Hortin GL (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52:1223-1237. doi: 10.1373/ clinchem.2006.069252
43. Hortin GL, Jortani SA, Ritchie JC, Valdes R, Chan DW (2006) Proteomics: a new diagnostic frontier. Clin Chem 52:1218-1222. doi: 10.1373/ clinchem.2006.067280
44. Hsich G, Kinney K, Gibbs CJ, Lee KH, Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335:924-930. doi: 10.1056/ NEJM199609263351303
45. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM (2005) Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 4:2000-2009. doi: 10.1074/ mcp.M500207-MCP200
46. Hye A, Lynham S, Thambisetty M et al (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129:3042-3050. doi: 10.1093/ brain/awl279
47. Imhof A, Kovari E, von Gunten A et al (2007) Morphological substrates of cognitive decline in nonagenarians and centenarians: A new paradigm? J Neurol Sci 257:72-79. doi: 10.1016/j.jns.2007.01.025
48. Issaq HJ (2001) The role of separation science in proteomics research. Electrophoresis 22:3629-3638. doi: 10.1002/ 1522-2683(200109)22:17<3629::AID-ELPS3629>3.0.CO;2-O
49. Jellinger KA (1997) Neuropathological staging of Alzheimer-related lesions: The challenge of establishing relations to age. Neurobiol Aging 18:369-375. doi: 10.1016/S0197-4580(97)00048-1
50. Jellinger KA (2009) Criteria for the neuropathological diagnosis of dementing disorders: Routes out of the swamp? Acta Neuropathol 117:101-110. doi: 10.1007/s00401-008-0466-z
51. Jin JH, Hulette C, Wang Y et al (2006) Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: Relevance to Parkinson disease. Mol Cell Proteomics 5:1193-1204. doi: 10.1074/mcp.M500382-MCP200
52. Jung SM, Lee K, Lee J et al (2008) Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Neurosci Lett 436:153-157. doi: 10.1016/j.neulet.2008.03.010
53. Keller JN, Schmitt FA, Scheff SW et al (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152-1156
54. Kim SH, Vlkolinsky R, Cairns N, Lubec G (2000) Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 57:1810-1816. doi: 10.1007/PL00000661
55. Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) The reduction of NADH ubiquinone oxidoreductase 24-and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci 68:2741-2750. doi: 10.1016/S0024-3205(01)01074-8
56. Korolainen MA, Nyman TA, Nyyssonen P, Hartikainen ES, Pirttila T (2007) Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem 53:657-665. doi: 10.1373/clinchem.2006.078014
57. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967:152-160. doi: 10.1016/S0006-8993(02)04243-9
58. le-Donne I, Milzani A, Gagliano N, Colombo R, Giustarini D, Rossi R (2008) Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid Redox Signal 10:445-473. doi: 10.1089/ ars.2007.1716
59. Leverenz JB, Umar I, Wang Q et al (2007) Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol 17:139-145. doi: 10.1111/j.1750-3639.2007.00048.x
60. Lia LJ, Cheng DM, Wang J et al (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279:37061-37068. doi: 10.1074/jbc.M403672200
61. Liang WS, Dunckley T, Beach TG et al (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: A reference data set. Physiol Genomics 33:240-256. doi: 10.1152/ physiolgenomics.00242.2007
62. Lubec G, Krapfenbauer K, Fountoulakis M (2003) Proteomics in brain research: Potentials and limitations. Prog Neurobiol 69:193-211. doi: 10.1016/S0301-0082(03)00036-4
63. Mattila KM, Frey H (1994) Alzheimer brain proteins investigated by 2-dimensional gel-electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis 15:721-725. doi: 10.1002/elps.1150150199
64. Mattila KM, Frey H (1995) Two-dimensional analysis of qualitative and quantitative changes in blood-cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl Theor Electrophor 4:189-196
65. McFarland MA, Ellis CE, Markey SP, Nussbaum RL (2008) Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics 7:2123-2137. doi: 10.1074/ mcp.M800116-MCP200
66. McLuckey SA, Wells JM (2001) Mass analysis at the advent of the 21st century. Chem Rev 101:571-606. doi: 10.1021/cr990087a
67. Meier-Ruge WA, Bertoni-Freddari C (1999) Mitochondrial genome lesions in the pathogenesis of sporadic Alzheimer's disease. Gerontology 45:289-297. doi: 10.1159/000022104
68. Mhyre TR, Loy R, Tariot PN et al (2008) Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging 29:1631-1643. doi: 10.1016/ j.neurobiolaging.2007.04.004
69. Molloy MP, Brzezinski EE, Hang JQ, McDowell MT, VanBogelen RA (2003) Overcoming technical variation and biological variation in quantitative proteomics. Proteomics 3:1912-1919. doi: 10.1002/pmic.200300534
70. Müller T, Jung K, Ullrich A et al (2008) Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples. Curr Alzheimer Res 5:562-571. doi: 10.2174/ 156720508786898488
71. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H (1990) Expression of monoamine oxidase-B activity in astrocytes of senile plaques. Acta Neuropathol 80:419-425. doi: 10.1007/BF00307697
72. Newman SF, Sultana R, Perluigi M et al (2007) An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85:1506-1514. doi: 10.1002/ jnr.21275
73. Ofarrell PH (1975) High-resolution 2-dimensional electrophoresis of proteins. J Biol Chem 250:4007-4021
74. Palagi PM, Hernandez P, Walther D, Appel RD (2006) Proteome informatics I: Bioinformatics tools for processing experimental data. Proteomics 6:5435-5444. doi: 10.1002/pmic.200600273
75. Portelius E, Zetterberg H, Andreasson U et al (2006) An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409:215-219. doi: 10.1016/j.neulet.2006.09.044
76. Portelius E, Hansson SF, Tran AJ et al (2008) Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 7:2114-2120. doi: 10.1021/pr7008669
77. Pratico D, Clark CM, Liun F, Lee VYM, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol 59:972-976. doi: 10.1001/ archneur.59.6.972
78. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118:140-146. doi: 10.1016/j.molbrainres.2003.08.005
79. Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13:1359-1362. doi: 10.1038/nm1653
80. Reed T, Pierce WM, Turner DM, Markesbery WR, Butterfield DA (2008) Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med [Epub ahead of print]
81. Ross PL, Huang YLN, Marchese JN et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-1169. doi: 10.1074/ mcp.M400129-MCP200
82. Ruetschi U, Zetterberg H, Podust VN et al (2005) Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196:273-281. doi: 10.1016/j.expneurol.2005.08.002
83. Schagger H, Ohm TG (1995) Human diseases with defects in oxidative phosphorylation. 2. F1F0 Atp-synthase defects in Alzheimer disease revealed by blue native polyacrylamide-gel electrophoresis. Eur J Biochem 227:916-921. doi: 10.1111/j.1432-1033.1995.tb20219.x
84. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 68:850-858. doi: 10.1021/ac950914h
85. Shiozaki A, Tsuji T, Kohno R et al (2004) Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation. J Alzheimers Dis 6:257-268
86. Simonsen AH, McGuire J, Hansson O et al (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64:366-370. doi: 10.1001/archneur.64.3.366
87. Simonsen AH, McGuire J, Podust VN et al (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 29:961-968. doi: 10.1016/j.neurobiolaging.2007.01.011
88. Sleno L, Volmer DA (2004) Ion activation methods for tandem mass spectrometry. J Mass Spectrom 39:1091-1112. doi: 10.1002/jms.703
89. Smith CD, Carney JM, Starkereed PE et al (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88:10540-10543. doi: 10.1073/ pnas.88.23.10540
90. Stamper C, Siegel A, Liang WS et al (2008) Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord 23:1588-1595. doi: 10.1002/mds.22184
91. Sultana R, Boyd-Kimball D, Poon HF et al (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27:1564-1576. doi: 10.1016/ j.neurobiolaging.2005.09.021
92. Sultana R, Poon HF, Cai J et al (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22:76-87. doi: 10.1016/j.nbd.2005.10.004
93. Sultana R, Boyd-Kimball D, Cai J et al (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11:153-164
94. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA (2007) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: A regional study. J Cell Mol Med 11:839-851. doi: 10.1111/j.1582-4934.2007.00065.x
95. Tannu N, Hemby SE (2006) Quantitation in two-dimensional fluorescence difference gel electrophoresis: Effect of protein fixation. Electrophoresis 27:2011-2015. doi: 10.1002/elps.200500710
96. Thiede B, Hohenwarter W, Krah A et al (2005) Peptide mass fingerprinting. Methods 35:237-247. doi: 10.1016/j.ymeth.2004.08.015
97. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27:1245-1253. doi: 10.1023/A:1020941929414
98. Ueno I, Sakai T, Yamaoka M, Yoshida R, Tsugita A (2000) Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Electrophoresis 21:1832-1845. doi: 10.1002/ (SICI)1522-2683(20000501)21:9<1832::AID-ELPS1832>3.0.CO;2-7
99. Utermann G, Hees M, Steinmetz A (1977) Polymorphism of Apolipoprotein-e and occurrence of dys-beta-lipoproteinemia in man. Nature 269:604-607. doi: 10.1038/269604a0
100. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 2′, 3′-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 22:547-553. doi: 10.1016/S0197-4580(01)00218-4
101. Wang Q, Woltjer RL, Cimino PJ et al (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament in tau binding protein. FASEB J 19:869-871. doi: 10.1096/fj.04-2370com
102. Wilson KE, Marouga R, Prime JE et al (2005) Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. Proteomics 5:3851-3858. doi: 10.1002/ pmic.200401255
103. Winkler W, Zellner M, Diestinger M et al (2008) Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics 7:193-203. doi: 10.1074/ mcp.M700137-MCP200
104. Wu WW, Wang GH, Baek SJ, Shen RF (2006) Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 5:651-658. doi: 10.1021/pr050405o
105. Yao Y, Taylor M, Davey F et al (2007) Interaction of amyloid binding alcohol dehydrogenase/A beta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 35:377-382. doi: 10.1016/j.mcn.2007.03.013
106. Yoo BC, Fountoulakis M, Cairns N, Lubec G (2001) Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22:172-179. doi: 10.1002/ 1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P
107. Yoo BC, Kim SH, Cairns N, Fountoulakis M, Lubec G (2001) Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 280:249-258. doi: 10.1006/bbrc.2000.4109
108. Zannis VI, Breslow JL (1981) Human very low-density lipoprotein apolipoprotein-e isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 20:1033-1041. doi: 10.1021/bi00507a059
109. Zhang RL, Barker L, Pinchev D et al (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4:244-256. doi: 10.1002/ pmic.200300495
110. Zhang J, Goodlett DR, Quinn JF et al (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7:125-133
111. Zhang J, Sokal I, Peskind ER et al (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129:526-529. doi: 10.1309/W01Y0B808EMEH12L
112. Zolg W (2006) The proteomic search for diagnostic biomarkers: Lost in translation? Mol Cell Proteomics 5:1720-1726. doi: 10.1074/ mcp.R600001-MCP200